This is the third and final (for now) installment of our 101 tour of spinal stimulation. We're joined again by Sam Maddox, U2FP's Scientific Advisory Board Director and veteran science journalist. Today, we discuss the commercialization of spinal stim, detailing the path that these therapies will need to traverse to arrive at the market.

We talk about how labs and businesses are organized and review some of the challenges they face, including obtaining FDA approval, getting funded, and organizing clinical trials and recruiting participants. Even after those hurdles are cleared and a therapy is ready to go to market, we speculate about the role clinical buy-in will play.

Finally, a quick shout out to you, our listeners for engaging with us during this series. We’ve had a lot of feedback and intend to address many of your questions and comments on the air soon. You can still reach out and tell us what you think at [email protected].

For more resources, including guest bios, related scientific studies and past conversations we've had with researchers studying spinal stimulation, go here: https://u2fp.org/get-educated/curecast/episode-73.html